300149 睿智医药
已收盘 11-06 15:00:00
资讯
新帖
简况
股市必读：睿智医药新发布《关于全资子公司与专业投资机构共同投资的公告》
证券之星 · 11-04
股市必读：睿智医药新发布《关于全资子公司与专业投资机构共同投资的公告》
睿智医药(300149.SZ)子公司拟1000万元参投武汉佰诺嘉泰创业投资合伙企业
智通财经 · 11-03
睿智医药(300149.SZ)子公司拟1000万元参投武汉佰诺嘉泰创业投资合伙企业
睿智医药（300149）披露董事、副总裁辞职公告，11月03日股价下跌5.1%
证券之星 · 11-03
睿智医药（300149）披露董事、副总裁辞职公告，11月03日股价下跌5.1%
11月3日睿智医药跌5.10%，银河康乐股票A基金重仓该股
证券之星 · 11-03
11月3日睿智医药跌5.10%，银河康乐股票A基金重仓该股
睿智医药：东方证券、开源证券等多家机构于11月2日调研我司
证券之星 · 11-02
睿智医药：东方证券、开源证券等多家机构于11月2日调研我司
股市必读：睿智医药三季报 - 第三季度单季净利润同比增长196.60%
证券之星 · 11-02
股市必读：睿智医药三季报 - 第三季度单季净利润同比增长196.60%
异动快报：睿智医药（300149）10月30日13点6分触及涨停板
证券之星 · 10-30
异动快报：睿智医药（300149）10月30日13点6分触及涨停板
图解睿智医药三季报：第三季度单季净利润同比增长196.60%
证券之星 · 10-30
图解睿智医药三季报：第三季度单季净利润同比增长196.60%
10月27日睿智医药跌5.09%，银河康乐股票A基金重仓该股
证券之星 · 10-27
10月27日睿智医药跌5.09%，银河康乐股票A基金重仓该股
股市必读：睿智医药新发布《第六届董事会第二十二次会议决议公告》
证券之星 · 10-22
股市必读：睿智医药新发布《第六届董事会第二十二次会议决议公告》
睿智医药：积极稳妥推进本次发行
证券之星 · 10-21
睿智医药：积极稳妥推进本次发行
睿智医药：截至到2026年10月10日，公司的股东人数为38,334人
证券之星 · 10-21
睿智医药：截至到2026年10月10日，公司的股东人数为38,334人
睿智医药（300149）10月16日主力资金净买入685.47万元
证券之星 · 10-19
睿智医药（300149）10月16日主力资金净买入685.47万元
睿智医药（300149）10月14日主力资金净卖出814.29万元
证券之星 · 10-15
睿智医药（300149）10月14日主力资金净卖出814.29万元
睿智医药（300149）10月13日主力资金净卖出568.50万元
证券之星 · 10-14
睿智医药（300149）10月13日主力资金净卖出568.50万元
睿智医药（300149）10月8日主力资金净卖出1643.37万元
证券之星 · 10-09
睿智医药（300149）10月8日主力资金净卖出1643.37万元
睿智医药（300149）9月30日主力资金净卖出210.01万元
证券之星 · 10-08
睿智医药（300149）9月30日主力资金净卖出210.01万元
睿智医药(300149)9月20日股东户数4.06万户，较上期增加2.65%
证券之星 · 09-28
睿智医药(300149)9月20日股东户数4.06万户，较上期增加2.65%
睿智医药：搭建AI辅助分子设计平台——XDrug.AI
证券之星 · 09-23
睿智医药：搭建AI辅助分子设计平台——XDrug.AI
睿智医药：公司将围绕全链条服务目标，积极补齐产业链薄弱环节
证券之星 · 09-22
睿智医药：公司将围绕全链条服务目标，积极补齐产业链薄弱环节
加载更多
公司概况
公司名称：
睿智医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2010-12-22
主营业务：
睿智医药科技股份有限公司的主营业务是提供生物药、化学药一站式医药研发及生产服务。公司的主要产品是化学业务、药效药动业务、大分子业务。
发行价格：
28.00
{"stockData":{"symbol":"300149","market":"SZ","secType":"STK","nameCN":"睿智医药","latestPrice":8.55,"timestamp":1793948595000,"preClose":8.8,"halted":0,"volume":19879904,"delay":0,"changeRate":-0.0284,"floatShares":482000000,"shares":505000000,"eps":-0.0139,"marketStatus":"已收盘","change":-0.25,"latestTime":"11-06 15:00:00","open":8.52,"high":8.81,"low":8.49,"amount":171000000,"amplitude":0.0364,"askPrice":8.56,"askSize":420,"bidPrice":8.55,"bidSize":1515,"shortable":0,"etf":0,"ttmEps":-0.0139,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.8,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":9.68,"lowLimit":7.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504985807,"isCdr":false,"pbRate":3.34,"roa":"--","roe":"--","epsLYR":0.03,"committee":0.711481,"marketValue":4318000000,"turnoverRate":0.0413,"status":1,"floatMarketCap":4118000000},"requestUrl":"/m/hq/s/300149","defaultTab":"news","newsList":[{"id":"2680798776","title":"股市必读：睿智医药新发布《关于全资子公司与专业投资机构共同投资的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680798776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680798776?lang=zh_cn&edition=full","pubTime":"2026-11-04 02:04","pubTimestamp":1793729097,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资子公司与专业投资机构共同投资的公告睿智医药全资子公司北海睿智创业投资有限公司拟以自有资金1,000万元增资武汉市佰诺嘉泰创业投资合伙企业，占其认缴出资总额的29.24%；该基金总规模为3,420万元，主要投向广州科恩泰生物医药科技有限公司，投资方式为认购其新增注册资本；本次投资无需提交公司董事会或股东会审议，不构成关联交易或重大资产重组；基金尚需完成工商变更及备案程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400003671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680728541","title":"睿智医药(300149.SZ)子公司拟1000万元参投武汉佰诺嘉泰创业投资合伙企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2680728541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680728541?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:35","pubTimestamp":1793705717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，睿智医药(300149.SZ)发布公告，公司全资子公司北海睿智创业投资有限公司(以下简称“北海睿智”)于近日与专业投资机构上海佰诺私募基金管理有限公司(以下简称“佰诺资本”)及其他有限合伙人签署了《武汉市佰诺嘉泰创业投资合伙企业(有限合伙)合伙协议》，北海睿智作为有限合伙人，拟以自有资金1,000万元对武汉佰诺嘉泰创业投资合伙企业(有限合伙)(以下简称“佰诺嘉泰”)进行增资，占合伙企业认缴出资总额的29.24%。公司子公司本次通过参与投资基金专项投资广州科恩泰生物医药科技有限公司，被投企业专注于激酶抑制剂的原始创新，致力于开发FIC创新激酶小分子抗肿瘤药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","300149","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680747406","title":"睿智医药（300149）披露董事、副总裁辞职公告，11月03日股价下跌5.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680747406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680747406?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:06","pubTimestamp":1793704008,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，睿智医药报收于8.19元，较前一交易日下跌5.1%，最新总市值为41.36亿元。该股当日开盘8.55元，最高8.56元，最低8.09元，成交额达2.91亿元，换手率为7.28%。睿智医药科技股份有限公司董事会于近日收到公司非独立董事、副总裁陈旺龙先生的书面辞职报告，陈旺龙先生因个人原因申请辞去公司第六届董事会非独立董事、副总裁职务。其辞职报告自送达公司董事会之日起生效。公司董事会对陈旺龙先生在任职期间的贡献表示衷心感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300037034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680749868","title":"11月3日睿智医药跌5.10%，银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680749868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680749868?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:14","pubTimestamp":1793697294,"startTime":"0","endTime":"0","summary":"证券之星消息，11月3日睿智医药跌5.10%，收盘报8.19元，换手率7.28%，成交量35.07万手，成交额2.91亿元。重仓睿智医药的公募基金请见下表：根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为银河基金的银河康乐股票A。银河康乐股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300033971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680766675","title":"睿智医药：东方证券、开源证券等多家机构于11月2日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2680766675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680766675?lang=zh_cn&edition=full","pubTime":"2026-11-02 23:05","pubTimestamp":1793631958,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年11月2日睿智医药发布公告称东方证券、开源证券、兴业证券、招商证券、国泰海通证券、西部证券、中泰证券、华源证券、国联民生于2026年11月2日调研我司。三方协同打通干湿实验闭环，强化“I+CRO”赋能能力，为客户提供更高效的研发决策与交付。前三季度，公司合同资产增量主要来自药效药动板块。睿智医药主营业务：医药研发及生产服务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200037977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600958","BK0188","BK1564","BK1147","300149","BK0183","BK0276","BK0028","03958","161027","BK0077","BK0216","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680202141","title":"股市必读：睿智医药三季报 - 第三季度单季净利润同比增长196.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680202141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680202141?lang=zh_cn&edition=full","pubTime":"2026-11-02 00:49","pubTimestamp":1793551747,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月30日主力资金净流入1.08亿元，占总成交额14.74%； 股本股东变化：截至2026年10月10日股东户数为3.83万户，较9月30日减少2.11%，户均持股增至1.32万股； 业绩披露要点：2026年第三季度单季度归母净利润1766.97万元，同比上升196.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200000170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679637552","title":"异动快报：睿智医药（300149）10月30日13点6分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2679637552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679637552?lang=zh_cn&edition=full","pubTime":"2026-10-30 13:10","pubTimestamp":1793337043,"startTime":"0","endTime":"0","summary":"证券之星10月30日盘中消息，13点6分睿智医药（300149）触及涨停板。其所属行业医疗服务目前上涨。领涨股为毕得医药。该股为医药，化学原料药，CAR-T疗法概念热股，当日医药概念上涨3.42%，化学原料药概念上涨3.13%，CAR-T疗法概念上涨3.02%。10月29日的资金流向数据方面，主力资金净流出407.77万元，占总成交额2.78%，游资资金净流入114.15万元，占总成交额0.78%，散户资金净流入293.63万元，占总成交额2.0%。近5日资金流向一览见下表：睿智医药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000029305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679623659","title":"图解睿智医药三季报：第三季度单季净利润同比增长196.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679623659","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679623659?lang=zh_cn&edition=full","pubTime":"2026-10-30 04:05","pubTimestamp":1793304303,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药2026年三季报显示，前三季度公司主营收入9.47亿元，同比上升15.97%；归母净利润-1332.36万元，同比下降287.89%；扣非净利润-1559.28万元，同比下降8.66%；其中2026年第三季度，公司单季度主营收入3.85亿元，同比上升35.96%；单季度归母净利润1766.97万元，同比上升196.6%；单季度扣非净利润1635.54万元，同比上升177.36%；负债率36.78%，投资收益-117.65万元，财务费用2367.65万元，毛利率25.91%。财报数据概要请见下图:本文数据来源于睿智医药2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000005996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678240231","title":"10月27日睿智医药跌5.09%，银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678240231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678240231?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:04","pubTimestamp":1793091853,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日睿智医药跌5.09%，收盘报7.65元，换手率2.56%，成交量12.34万手，成交额9690.85万元。重仓睿智医药的公募基金请见下表：根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为银河基金的银河康乐股票A。银河康乐股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677099916","title":"股市必读：睿智医药新发布《第六届董事会第二十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677099916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677099916?lang=zh_cn&edition=full","pubTime":"2026-10-22 02:29","pubTimestamp":1792607349,"startTime":"0","endTime":"0","summary":"关于补选独立董事的公告第六届董事会第二十二次会议审议通过《关于补选独立董事的议案》，提名石春茂为独立董事候选人；其已取得深交所认可的独立董事资格证书，未持有公司股份，与主要股东及其他董监高无关联关系，未受过处罚或被立案稽查；补选后独立董事占比不低于三分之一；该事项尚需深交所审核无异议后提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200001571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677648905","title":"睿智医药：积极稳妥推进本次发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2677648905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677648905?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:48","pubTimestamp":1792543692,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药10月20日在投资者关系平台上答复投资者关心的问题。公司管理层持续聚焦主业经营，努力提升公司内在价值，也充分理解投资者对本次定增项目进度的关切。公司将在批复有效期内，按照规定履行相关程序，积极稳妥推进本次发行，并按要求及时履行信息披露义务。关于经营业绩，公司 2026 年第三季度报告预约披露时间为 10 月 30 日，具体经营数据请以公司定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677489636","title":"睿智医药：截至到2026年10月10日，公司的股东人数为38,334人","url":"https://stock-news.laohu8.com/highlight/detail?id=2677489636","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677489636?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:42","pubTimestamp":1792543332,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年10月10日公司的股东人数是多少？谢谢睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。截至到2026年10月10日，公司的股东人数为38,334人。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676571828","title":"睿智医药（300149）10月16日主力资金净买入685.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676571828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676571828?lang=zh_cn&edition=full","pubTime":"2026-10-19 09:15","pubTimestamp":1792372551,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月16日收盘，睿智医药报收于7.97元，下跌3.28%，换手率5.97%，成交量28.75万手，成交额2.39亿元。10月16日的资金流向数据方面，主力资金净流入685.47万元，占总成交额2.87%，游资资金净流入516.89万元，占总成交额2.16%，散户资金净流出1202.37万元，占总成交额5.03%。融券方面，融券卖出100.0股，融券偿还0.0股，融券余量3.95万股，融券余额31.48万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900002537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675379309","title":"睿智医药（300149）10月14日主力资金净卖出814.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675379309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675379309?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:17","pubTimestamp":1792027068,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月14日收盘，睿智医药报收于8.45元，下跌4.63%，换手率3.36%，成交量16.2万手，成交额1.39亿元。10月14日的资金流向数据方面，主力资金净流出814.29万元，占总成交额5.88%，游资资金净流入773.76万元，占总成交额5.58%，散户资金净流入40.53万元，占总成交额0.29%。融券方面，融券卖出0.0股，融券偿还300.0股，融券余量3.96万股，融券余额33.46万元。睿智医药主营业务：医药研发及生产服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500008297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675399367","title":"睿智医药（300149）10月13日主力资金净卖出568.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675399367","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675399367?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:13","pubTimestamp":1791940436,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，睿智医药报收于8.86元，下跌2.64%，换手率4.7%，成交量22.63万手，成交额1.98亿元。10月13日的资金流向数据方面，主力资金净流出568.5万元，占总成交额2.87%，游资资金净流入381.65万元，占总成交额1.93%，散户资金净流入186.85万元，占总成交额0.94%。融券方面，融券卖出1500.0股，融券偿还0.0股，融券余量3.99万股，融券余额35.35万元。睿智医药主营业务：医药研发及生产服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674888108","title":"睿智医药（300149）10月8日主力资金净卖出1643.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674888108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674888108?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:19","pubTimestamp":1791508744,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，睿智医药报收于9.45元，下跌4.55%，换手率5.32%，成交量25.62万手，成交额2.46亿元。10月8日的资金流向数据方面，主力资金净流出1643.37万元，占总成交额6.68%，游资资金净流入254.44万元，占总成交额1.03%，散户资金净流入1388.93万元，占总成交额5.65%。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量4.0万股，融券余额37.8万元。睿智医药主营业务：医药研发及生产服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900007342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673604977","title":"睿智医药（300149）9月30日主力资金净卖出210.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673604977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673604977?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:08","pubTimestamp":1791421691,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，睿智医药报收于9.9元，上涨2.7%，换手率7.0%，成交量33.69万手，成交额3.35亿元。9月30日的资金流向数据方面，主力资金净流出210.01万元，占总成交额0.63%，游资资金净流出473.36万元，占总成交额1.41%，散户资金净流入683.37万元，占总成交额2.04%。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量4.0万股，融券余额39.6万元。睿智医药主营业务：医药研发及生产服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670356622","title":"睿智医药(300149)9月20日股东户数4.06万户，较上期增加2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670356622","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670356622?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:51","pubTimestamp":1790589072,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2026年9月20日公司股东户数为4.06万户，较9月10日增加1049.0户，增幅为2.65%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至9月20日，医疗服务行业平均股东户数为4.72万户。从股价来看，2026年9月10日至2026年9月20日，睿智医药区间涨幅为3.12%，在此期间股东户数增加1049.0户，增幅为2.65%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800023400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486395","title":"睿智医药：搭建AI辅助分子设计平台——XDrug.AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669486395?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:48","pubTimestamp":1790167711,"startTime":"0","endTime":"0","summary":"在生物大分子领域搭建AI辅助抗体发现、多肽虚拟筛选平台；在小分子领域搭建成药性预测平台，对候选分子进行ADMET性质预测及优化筛选，并将人工智能辅助药物设计能力延伸至客户服务，通过大数据分析与机器学习建模，为客户提供分子优化与成药性预测服务；此外，公司搭建了AI 辅助分子设计平台——XDrug.AI，推动药物设计能力由方法工具向可交付的研发服务实现工程化转化。除此之外，公司联合外部AI专家团队合作，共建AI知识库与靶点发现平台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300038313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669112867","title":"睿智医药：公司将围绕全链条服务目标，积极补齐产业链薄弱环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2669112867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669112867?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:54","pubTimestamp":1790063652,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司一直说增发项目完成以后就会启动资产并购。可增发一直不完成。请问公司增发完成以后 还会资产并购吗？主要是哪些方向的资产?睿智医药回复：尊敬的投资者，您好！感谢对公司的关注，公司将结合资本市场环境与公司实际情况，积极稳妥推进本次定增发行工作，并严格按照监管要求及时履行信息披露义务。此外，公司将围绕全链条服务目标，积极补齐产业链薄弱环节。请关注公司的相关公告。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200023949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794106237301,"stockEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.1364},{"period":"3month","weight":-0.1795},{"period":"6month","weight":-0.1493},{"period":"1year","weight":-0.2227},{"period":"ytd","weight":-0.1056}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"睿智医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"38334人(较上一季度减少2.11%)","perCapita":"12562股","listingDate":"2010-12-22","address":"广东省江门市江海区胜利南路164号","registeredCapital":"50498万元","survey":" 睿智医药科技股份有限公司的主营业务是提供生物药、化学药一站式医药研发及生产服务。公司的主要产品是化学业务、药效药动业务、大分子业务。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"睿智医药,300149,睿智医药股票,睿智医药股票老虎,睿智医药股票老虎国际,睿智医药行情,睿智医药股票行情,睿智医药股价,睿智医药股市,睿智医药股票价格,睿智医药股票交易,睿智医药股票购买,睿智医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}